ALNOX.PAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...

Stats
本日の出来高	10.21M
平均出来高	4.35M
時価総額	0.00
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.187
ATR14	€0 (0.00%)

NOXXON Pharma NV 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

NOXXON Pharma NV 財務諸表

Annual	2021
収益:	€0.00
総利益:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2021
収益:	€0.00
総利益:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2020
収益:	€0.00
総利益:	€0.00 (0.00 %)
EPS:	€-32.16

FY	2019
収益:	€0.00
総利益:	€-1.03M (0.00 %)
EPS:	€-7.72

Financial Reports:

No articles found.

NOXXON Pharma NV

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.